A New Frontier in TYK2 Inhibition InventisBio has officially announced positive topline results from its pivotal Phase III clinical trial for nomelcitinib. As a selective TYK2 (Tyrosine Kinase 2) inhibitor, this novel therapeutic is positioned to offer a significant advancement in the management of autoimmune conditions. Study Success and Efficacy The Phase III study was…